The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer.
Sara M. Tolaney
No relevant relationships to disclose
Hao Guo
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Katherine Larrabee
No relevant relationships to disclose
Jane E. Brock
No relevant relationships to disclose
Nikhil Wagle
No relevant relationships to disclose
Eliezer Mendel Van Allen
No relevant relationships to disclose
Cloud Paweletz
No relevant relationships to disclose
Elena Ivanova
No relevant relationships to disclose
Pasi A. Janne
No relevant relationships to disclose
Beth Overmoyer
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Geoffrey Shapiro
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose